New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)

St. Jude Reference #SJ-02-0008 and SJ-05-0017


The following new uses for chloroquine and chloroquine analogs are provided:

  • prevent hypoxia-reperfusion injury
  • protect against lethal, "low dose rate" radiation
  • treat metabolic syndrome (clinical trials ongoing)



chloroquine, metabolic syndrome, hypoxia-reperfusion injury, radiation


Granted Patents or Published Applications

U.S. Patent Nos. 6,916,627; 7,108,992; 7,160,692; 7,279,290; and 8,440,695, Pending U.S. Pub. 2013/0296237


Related Scientific References

Bakkenist, C. et al. ” DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation”, Nature 421: 499-506 (2003); see also related commentary by Bartek, J. and Lukas, J., Nature 421: 486-488 (2003);

Kastan, M.B. and Bartek, J., “Cell-cycle checkpoints and cancer”, Nature 432: 316-323 (2004);

Schneider, J.G. et al., “ATM-dependent suppression of stress signaling reduces vascular disease inmetabolic syndrome”, Cell Metab.4: 377-389 (Nov. 2006); see also related commentary by Shoelson, S., Cell Metab.4: 337-338 (Nov. 2006).


Licensing Opportunities

We are currently seeking nonexclusive licensing opportunities in the described fields for the development and use of this technology.

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.